Monoclonal antibodyPhase 3 trialInvestigational
Margetuximab
How it works
Blocks the HER2 receptor on cancer cells, blocking growth signals and flagging the cells for immune destruction.
Cancer types
Colorectal Cancer— HER2-positive
Efficacy
In clinical trials, Margetuximab improved progression-free survival in patients with HER2-positive metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Costs of Cancer Treatments in the US and China | Breast Cancer | phase-3 | Margetuximab plus chemotherapy had a gain of 0.11 and 0.09 QALYs compared to trastuzumab plus chemotherapy in the US and China, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.